Jaya Padmanabhan is a Psychiatry physician affiliated with Takeda. OpenAlex indexes 47 publications with 1,811 citations (h-index 21).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
330 Brookline Ave
Kirstein-2
Boston, MA 02215
Telephone
617-667-4074Registry record last updated 17 Mar 2018.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alnylam Pharmaceuticals Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2019)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
93.4%SSRI33.5%Sertraline Hcl61%Trazodone Hcl23%Escitalopram Oxalate17%Part D<11 patientsAtypical Antipsychotic27.4%Aripiprazole44%Olanzapine32%Risperidone24%Part D<11 patients+ 4 more classes in this area
Cardiovascular
6.6%Calcium channel blocker6.6%Amlodipine Besylate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Population Pharmacokinetic and Exposure‐Response Analysis of the Cognitive Effects of TAK‐071 in Participants With Parkinson Disease and Cognitive Impairment
Clinical Pharmacology in Drug Development
2025 - Using a smartwatch and smartphone to assess early Parkinson’s disease in the WATCH-PD study
npj Parkinson s Disease
2023
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”